Cardiovascular safety of central nervous system stimulants in children and adolescents: Population based cohort study

BMJ (Online)

Volumn 345, Issue 7869, 2012, Pages

  Winterstein, Almut G ^a   Gerhard, Tobias ^b   Kubilis, Paul ^a   Saidi, Arwa ^c   Linden, Stephan ^a   Crystal, Stephen ^d   Zito, Julie ^e   Shuster, Jonathan J ^c   Olfson, Mark ^f  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^d The State University of New Jersey   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

^f NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHETAMINE; ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; METHYLPHENIDATE; NEUROLEPTIC AGENT;

ACUTE HEART INFARCTION; ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION DEFICIT DISORDER; BIPOLAR DISORDER; CARDIOVASCULAR RISK; CHILD; CHILD DEATH; CHILD HEALTH CARE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEMOGRAPHY; DEPRESSION; DRUG SAFETY; FEMALE; FOLLOW UP; HEART VENTRICLE ARRHYTHMIA; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MENTAL DISEASE; MENTAL HEALTH; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SCHOOL CHILD; SIDE EFFECT; SOCIAL STATUS; STROKE; SUDDEN DEATH; SURVIVAL RATE; TREATMENT DURATION; EPIDEMIOLOGY; HEART DISEASE; UNITED STATES;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; EPIDEMIOLOGIC METHODS; FEMALE; HEART DISEASES; HUMANS; MALE; MEDICAID; STROKE; UNITED STATES;

EID: 84864886581     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.e4627     Document Type: Article

References (32)

1. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006;354:1445-8.
2. Perrin JM, Friedman RA, Knilans TK, Group BBW, Surgery SoCaC. Cardiovascular monitoring and stimulant drugs for attention-deficit/ hyperactivity disorder. Pediatrics 2008;122:451-3.
3. Vetter VL, Elia J, Erickson C, Berger S, Blum N, Uzark K, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation 2008;117:2407-23. (Pubitemid 351653546)
4. Bélanger SA, Warren AE, Hamilton RM, Gray C, Gow RM, Sanatani S, et al. Cardiac risk assessment before the use of stimulant medications in children and youth. Paediatr Child Health 2009;14:579-92.
5. Biederman J, Mick E, Surman C, Doyle R, Hammerness P, Harpold T, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006;59:829-35.
6. Weisler RH, Biederman J, Spencer TJ, Wilens TE. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 2005;10:35-43. (Pubitemid 43010496)
7. Samuels JA, Franco K, Wan F, Sorof JM. Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol 2006;21:92-5. (Pubitemid 43040200)
8. Stowe CD, Gardner SF, Gist CC, Schulz EG, Wells TG. 24-hour ambulatory blood pressure monitoring in male children receiving stimulant therapy. Ann Pharmacother 2002;36:1142-9. (Pubitemid 34755788)
9. Findling RL, Short EJ, Manos MJ. Short-term cardiovascular effects of methylphenidate and adderall. J Am Acad Child Adolesc Psychiatry 2001;40:525-9. (Pubitemid 32374269)
10. Winterstein AG, Gerhard T, Shuster J, Johnson M, Zito JM, Saidi A. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics 2007;120:e1494-501. (Pubitemid 350223669)
11. Graham J, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry 2011;20:17-37.
12. Olfson M, Huang C, Gerhard T, Winterstein A, Crystal S, Allison P, et al. Stimulants and cardiovascular events in youth with attention-deficit/ hyperactivity disorder. J Am Acad Adolesc Psychiatry 2012;51:147-56.
13. Schelleman H, Bilker WB, Strom BL, Kimmel SE, Newcomb C, Guevara JP, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics 2011;127:1102-10.
14. Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med 2011;365:1896-904.
15. Chung CP, Murray KT, Stein CM, Hall K, Ray WA. A computer case definition for sudden cardiac death. Pharmacoepidemiol Drug Saf 2010;19:563-72.
16. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
17. Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. Springer, 2001.
18. Cox DR. Regression models and life-tables. J R Stat Soc Series B Stat Methodol 1972;34:187.
19. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. Wiley, 1980.
20. Herndon JE, Harrell FE. The restricted cubic spline as baseline hazard in the proportional hazards model with step function time-dependent covariables. Stat Med 1995;14:2119-29.
21. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol 1993;138:923-36. (Pubitemid 24002359)
22. Cornfield J. A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix. J Natl Cancer Inst 1951;11:1269-75.
23. Zito JM, Safer DJ, dosReis S, Magder LS, Gardner JF, Zarin DA. Psychotherapeutic medication patterns for youths with attention-deficit/ hyperactivity disorder. Arch Pediatr Adolesc Med 1999;153:1257-63.
24. Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H, et al. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother 2008;42:24-31.
25. McCarthy SC, Potts N, Taylor L, Wong E. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the General Practice Research Database. Drug Safety 2009;32:1089-96.
26. Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 2003;158:915-20. (Pubitemid 37323253)
27. Chen CY, Gerhard T, Winterstein AG. Determinants of initial pharmacological treatment for youths with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2009;19:187-95.
28. Ray WA, Meredith S, Thapa PB, Meador KG, Hall K, Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 2001;58:1161-7. (Pubitemid 33121508)
29. Ray WA, Chung CP, Murray KT, Hall K, Stein CM. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009;360:225-35.
30. Umana E, Solares CA, Alpert MA. Tachycardia-induced cardiomyopathy. Am J Med 2003;114:51-5. (Pubitemid 36126516)
31. El Hajjar M, Hermida JS, Caron FM, Nassif D, Bourges-Petit E, Maingourd Y. [Tachycardia-induced cardiomyopathy in children: a difficult diagnosis but a reversible form of left ventricular dysfunction.] Arch Pediatr 2004;11:24-8.
32. Shinbane JS, Wood MA, Jensen DN, Ellenbogen KA, Fitzpatrick AP, Scheinman MM. Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies. J Am Coll Cardiol 1997;29:709-15. (Pubitemid 27128241)